

References

I-158

1. Ding H, Chang J, Liu L, et al. High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study. *Int J Hematol*. 2015;181–187.
2. Jing X, Zhang Z, Wu P, et al. Efficacy and tolerance of pegaspargase, gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly-diagnosed extranodal nature killer (NK)/T cell lymphoma. *Leukemia Research*. 2016;26–31.
3. Zhou Z, Li X, Chen C, et al. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients. *Ann Hematol*. 2014;1889– 1894.
4. MICROMEDEX®SOLUTIONS Compendia. 2020. Pegaspargase.
5. NCCN Drugs & Biologics Compendium™. Pegaspargase. 2020. National Comprehensive Cancer Network (NCCN).
6. Clinical Pharmacology Compendia. [database online]. 2020. Tampa FL: Gold Standard, Inc. Pegaspargase.
7. Oncaspar® (pegaspargase) ([package insert]. Gaithersburg, MD. Sigma-Tau Pharmaceuticals, Inc.: 2014. Revised 08/2019.
8. Egler R A, Ahuja S P, Matloub Y. L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. *Journal of Pharmacology and Pharmacotherapeutics*. 2016;62-71.
9. Salzer WL, Asselin BL, Plourde PV, et al. Development of asparaginase *Erwinia chrysanthemi* for the treatment of acute lymphoblastic leukemia. *N.Y. Acad. Sci*.2014;81-92.
10. Plourde PV, Jeha S, Hijiya N, et al. Safety Profile of Asparaginase *Erwinia chrysanthemi* in a Large Compassionate-Use Trial. *Pediatr Blood Cancer*. 2014;1232–1238.
11. MICROMEDEX®SOLUTIONS Compendia. 2020. Asparaginase *Erwinia Chrysanthemi*.
12. Clinical Pharmacology Compendia. [database online]. 2020. Tampa FL: Gold Standard, Inc. Asparaginase *Erwinia Chrysanthemi*.
13. NCCN Drugs & Biologics Compendium™. Asparaginase *Erwinia Chrysanthemi*. 2020. National Comprehensive Cancer Network (NCCN).
14. NCCN Drugs & Biologics Compendium™. Calaspargase pegol-mknl. 2020. National Comprehensive Cancer Network (NCCN).

15. Clinical Pharmacology Compendia. [database online]. 2020. Tampa FL: Gold Standard, Inc. Calaspargase pegol-mknl.
16. Asparlas™ (calaspargae pegol-mknl). [package insert]. Servier Pharmaceuticals LLC. Boston, MA. 06/2020.
17. Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified shortcourse multidrug chemotherapy: results of a trial ALL-REZ BFM 90. *J Clin Oncol*. 28(14);2010:2339-2347.
18. Erwinaze® (asparaginase *Erwinia chrysanthemi*) [package insert]. Palo Alto, CA. Jazz Pharmaceuticals, Inc. 2011. Revised 12/2019.
19. MICROMEDEX®SOLUTIONS Compendia. 2020. Calaspargase pegol-mknl.
20. Zhao Q, Fan S, Chang Y, et al. Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III–IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus. *Cancer Management and Research*. 2019;11:3555-3564.